List of Immuno-Oncology Companies in France - 9

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply. Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development. We are currently envisaging clinical collaborations. Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.

We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases: - OncoMimics™: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas. - EndoMimics™: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is a potent local inducer of IL-10 designed to provide improved therapeutic outcomes for patients with IBD. In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered with AstraZeneca (2018). It is currently in phase 2 clinical trial in NSCLC. The second program, at preclinical stage, targets a new regulator of the immune response in order to overcome resistance to anti-PD1 antibodies. The investors are initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative.

OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company’s most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides.

Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.

Stimunity is a preclinical-stage startup company which develops best-in-class drugs on the STING pathway to activate the innate immune system to fight back infectious pathogens or cancer. It was founded in 2016 and is focused on the development of STING agonists in cancer.

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinson's Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.